Getein Biotech Inc (603387) - Total Assets
Based on the latest financial reports, Getein Biotech Inc (603387) holds total assets worth CN¥3.70 Billion CNY (≈ $541.26 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Getein Biotech Inc - Total Assets Trend (2012–2025)
This chart illustrates how Getein Biotech Inc's total assets have evolved over time, based on quarterly financial data. Also see Getein Biotech Inc (603387) market capitalisation for the company's overall valuation and market capitalisation.
Getein Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Getein Biotech Inc's total assets of CN¥3.70 Billion consist of 61.3% current assets and 38.7% non-current assets. Review 603387 total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.4% |
| Accounts Receivable | CN¥359.52 Million | 9.6% |
| Inventory | CN¥183.83 Million | 4.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥201.30 Million | 5.4% |
| Goodwill | CN¥12.02 Million | 0.3% |
Asset Composition Trend (2012–2025)
This chart illustrates how Getein Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Getein Biotech Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Getein Biotech Inc's current assets represent 61.3% of total assets in 2025, an increase from 48.0% in 2012.
- Cash Position: Cash and equivalents constituted 8.4% of total assets in 2025, down from 22.3% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 4.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 9.6% of total assets.
Getein Biotech Inc Competitors by Total Assets
Key competitors of Getein Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic plc
SA:MDTC34
|
Brazil | R$93.03 Billion |
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Medartis Holding AG
SW:MED
|
Switzerland | CHF610.05 Million |
|
Xiangyu Medical Co. Ltd. A
SHG:688626
|
China | CN¥3.27 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Beijing Chunlizhengda Medical Instruments Co Ltd
SHG:688236
|
China | CN¥3.54 Billion |
|
PULSION Medical Systems SE
MU:PUS
|
Germany | €35.15 Million |
Getein Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.21 | 2.09 | 3.12 |
| Quick Ratio | 2.94 | 1.87 | 2.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.60 Billion | CN¥980.12 Million | CN¥1.41 Billion |
Getein Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Getein Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.47 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | 1.3% |
| Total Assets | CN¥3.76 Billion |
| Market Capitalization | $699.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values Getein Biotech Inc's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Getein Biotech Inc's assets grew by 1.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Getein Biotech Inc (2012–2025)
The table below shows the annual total assets of Getein Biotech Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.76 Billion ≈ $549.61 Million |
+1.31% |
| 2024-12-31 | CN¥3.71 Billion ≈ $542.51 Million |
-1.70% |
| 2023-12-31 | CN¥3.77 Billion ≈ $551.91 Million |
+2.56% |
| 2022-12-31 | CN¥3.68 Billion ≈ $538.12 Million |
+17.19% |
| 2021-12-31 | CN¥3.14 Billion ≈ $459.18 Million |
+16.22% |
| 2020-12-31 | CN¥2.70 Billion ≈ $395.09 Million |
+34.49% |
| 2019-12-31 | CN¥2.01 Billion ≈ $293.78 Million |
+27.84% |
| 2018-12-31 | CN¥1.57 Billion ≈ $229.80 Million |
+23.99% |
| 2017-12-31 | CN¥1.27 Billion ≈ $185.34 Million |
+191.79% |
| 2016-12-31 | CN¥434.09 Million ≈ $63.52 Million |
+32.31% |
| 2015-12-31 | CN¥328.08 Million ≈ $48.01 Million |
+58.91% |
| 2014-12-31 | CN¥206.45 Million ≈ $30.21 Million |
+33.64% |
| 2013-12-31 | CN¥154.49 Million ≈ $22.61 Million |
+72.07% |
| 2012-12-31 | CN¥89.78 Million ≈ $13.14 Million |
-- |
About Getein Biotech Inc
Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection, chemiluminescence detection, biochemical analysis, molecular testing, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical … Read more